Production (Stage)
Iovance Biotherapeutics, Inc.
IOVA
$2.21
$0.167.81%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 16.52% | 16.18% | 5.31% | -5.10% | -9.23% |
| Total Depreciation and Amortization | 19.89% | 31.63% | 42.97% | 65.09% | 70.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 91.37% | 76.49% | 21.43% | -7.41% | -29.03% |
| Change in Net Operating Assets | -310.19% | -1,779.40% | -371.82% | -412.18% | -383.44% |
| Cash from Operations | 12.98% | 2.44% | -2.29% | -16.02% | -20.55% |
| Capital Expenditure | 36.97% | 50.34% | 52.12% | 40.19% | -41.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | 75.28% | 75.42% | 73.42% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 132.85% | -141.13% | -185.24% | -151.93% | -139.69% |
| Cash from Investing | 107.37% | 37.90% | -135.47% | -415.21% | -229.94% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -12.31% | -13.36% | -38.72% | 23.04% | -10.53% |
| Repurchase of Common Stock | -147.91% | -360.04% | -366.23% | -180.99% | -21.60% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -14.55% | -15.62% | -40.34% | 22.26% | -10.86% |
| Foreign Exchange rate Adjustments | 114.18% | 80.26% | 163.50% | 110.93% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 109.15% | -4.26% | -178.15% | -133.71% | -190.66% |